PharmaCorp Rx (PCRX) Investor presentation summary

Industry overview and growth drivers

• Pharmacy sector in Canada is recession-resilient, driven by essential healthcare spending and government funding.

• Aging population and expanded pharmacist scope of practice are increasing prescription demand and revenue opportunities.

• Patient loyalty and recurring relationships support predictable revenue streams.

• Demographic trends show a rising percentage of Canadians aged 65+, fueling industry tailwinds.

Business model and acquisition strategy

• Operates a buy, integrate, and operate model focused on independent pharmacies across Canada.

• Holds exclusive right of first refusal (ROFR) on over 1,150 PharmaChoice Canada stores, ensuring unique pipeline access.

• Targets pharmacies with ~$2M+ annual revenue and ~$350K+ adjusted EBITDA, often using share consideration for acquisitions.

• Seller incentives include flexible exit options, equity upside, and legacy preservation through co-ownership loans.

Post-acquisition value creation

• Implements front shop optimization, planograms, and new product categories to boost margins.

• Enhances pharmacy profitability via strategic drug buying, automation, and workflow technology.

• Targets 7.5–15% adjusted EBITDA lift over three years post-acquisition.

• Integration playbook includes 30-day stabilization, six-month optimization, and one-year full integration for scalable growth.